The chloride paradigm shift in heart failure: From neglected ion to keystone of precision diuretic therapy
Por:
Mazón-Ruiz, J, Banegas-Deras, EJ, Fernández-Rodríguez, JM, Domingo, M, de la Espriella, R, Llàcer, P, Cobo-Marcos, M, Trullàs, JC, Biegus, J, Bayés-Genís, A, Nuñez, J and Romero-González, G
Publicada:
1 dic 2025
Ahead of Print:
1 oct 2025
Resumen:
Chloride, together with sodium, is one of the major extracellular ions and plays a critical yet often overlooked role in the pathophysiology of heart failure (HF). Beyond its passive role in maintaining electroneutrality and osmotic balance, chloride actively contributes to renal tubular transport via Na+-Cl- cotransporter (NCC) and Na+-K+-2Cl(-) cotransporter (NKCC), regulates acid-base homeostasis through bicarbonate exchange, and modulates neurohormonal activity by influencing renin release at the macula densa. In HF, hypochloraemia (whether dilutional or due to true ionic depletion) activates maladaptive mechanisms including enhanced sodium reabsorption, metabolic alkalosis, and sustained activation of the renin-angiotensin-aldosterone system. These alterations collectively exacerbate fluid retention, promote diuretic resistance, and worsen congestion. Emerging evidence suggests that low serum chloride levels are independently associated with higher mortality, reduced natriuretic response, and poorer decongestion outcomes. This review synthesizes the pathophysiological and clinical significance of chloride in HF and examines emerging therapeutic strategies aimed at restoring chloride homeostasis and improving diuretic response. These include sodium-free chloride formulations, chloride-sparing diuretics, and hypertonic saline solutions, with trials such as SMAC-HF and SALT-HF suggesting clinical benefit, particularly in hypochloraemic patients. Novel technologies, such as automated chloride-balanced diuresis systems, represent a promising tool for individualized fluid management. Recognizing hypochloraemia as a modifiable therapeutic target (rather than a bystander) may lead to a paradigm shift in the approach to congestion and volume overload in HF. A chloride-guided strategy offers the potential for more effective and personalized decongestive therapy.
[GRAPHICS]
.
Filiaciones:
Mazón-Ruiz, J:
Hosp Carmen & Severo Ochoa, Nephrol Dept, Cangas De Narcea, Spain
Banegas-Deras, EJ:
Hosp Carmen & Severo Ochoa, Nephrol Dept, Cangas De Narcea, Spain
Fernández-Rodríguez, JM:
Hosp Univ Cent Asturias, Internal Med Dept, Oviedo, Spain
:
Hosp Badalona Germans Trias & Pujol, Cardiol Dept, Heart Failure Unit, Badalona, Spain
de la Espriella, R:
Hosp Clin Univ, Inst Invest Sanitaria Hosp Clin Valencia INCL, Cardiol Dept, Valencia, Spain
Ctr Invest Biomed Red Enfermedades Cardiovasc CIBE, Madrid, Spain
Univ Valencia, Valencia, Spain
Llàcer, P:
Hosp Univ Ramon & Cajal, Internal Med Dept, Inst Ramon & Cajal Invest Sanitaria Irycis, Madrid, Spain
Univ Alcala, Fac Med & Hlth Sci, Dept Med & Med Specialties, Madrid, Spain
Cobo-Marcos, M:
Ctr Invest Biomed Red Enfermedades Cardiovasc CIBE, Madrid, Spain
Hosp Univ Puerta Hierro, Cardiol Dept, Madrid, Spain
Trullàs, JC:
Hosp Olot Comarcal Garrotxa, Internal Med Dept, Girona, Spain
Univ Vic Univ Cent Catalunya, Fac Med, Lab Reparacio & Regeneracio Tissular TR2Lab, Carretera De Roda, Spain
Biegus, J:
Wroclaw Med Univ, Dept Cardiol, Clin Dept Intens Cardiac Care, Fac Med,Inst Heart Dis, Wroclaw, Poland
:
Ctr Invest Biomed Red Enfermedades Cardiovasc CIBE, Madrid, Spain
Univ Autonoma Barcelona, Hosp Univ Germans Trias & Pujol, Heart Inst, Barcelona, Spain
Nuñez, J:
Hosp Clin Univ, Inst Invest Sanitaria Hosp Clin Valencia INCL, Cardiol Dept, Valencia, Spain
Ctr Invest Biomed Red Enfermedades Cardiovasc CIBE, Madrid, Spain
Univ Valencia, Valencia, Spain
Romero-González, G:
Hosp Badalona Germans Trias & Pujol, Nephrol Dept, Badalona, Spain
Germans Trias & Pujol Res Inst, REMAR IGTP Grp, Badalona, Spain
Int Renal Res Inst Vicenza, Vicenza, Italy
Bronze
|